LAG3-centered multiplex immune profiling as a prognostic biomarker in hepatocellular carcinoma patients receiving Anti-PD-1 antibodies plus lenvatinib therapy - Top-Institutions - MDSpire

LAG3-centered multiplex immune profiling as a prognostic biomarker in hepatocellular carcinoma patients receiving Anti-PD-1 antibodies plus lenvatinib therapy

  • By

  • Juan Zhang

  • Mingzhen Zhou

  • Ziyue Jin

  • Wenyan Cao

  • Xuena Zhang

  • Fanlai Meng

  • Haiyan Wei

  • Jie Shen

  • July 1, 2026

  • 0 min

Share

Top Institutions in Oncology

Brief introduction explaining scope and methodology.

  • #1

    Nanjing Drum Tower Hospital
    Nanjing Drum Tower Hospital

    Nanjing, Jiangsu

    Key Differentiators

    • Oncology

  • #2

    Memorial Sloan Kettering Cancer Center
    Memorial Sloan Kettering Cancer Center

    New York, New York

    Key Differentiators

    • Oncology

  • #3

    Mount Sinai Liver Cancer Program
    Mount Sinai Liver Cancer Program

    New York, New York

    Key Differentiators

    • Oncology

  • #4

    Medical University of Vienna
    Medical University of Vienna

    Vienna, Vienna

    Key Differentiators

    • Oncology

  • #5

    Hiroshima University Hospital
    Hiroshima University Hospital

    Hiroshima, Hiroshima

    Key Differentiators

    • Oncology

Original Source(s)

LAG3-centered multiplex immune profiling as a prognostic biomarker in hepatocellular carcinoma patients receiving Anti-PD-1 antibodies plus lenvatinib therapy

  • by Juan Zhang, Mingzhen Zhou, Ziyue Jin, Wenyan Cao, Xuena Zhang, Fanlai Meng, Haiyan Wei, Jie Shen

  • July 1, 2026

Related Content

Harnessing AI-driven approaches for detecting metabolic dysfunction-associated steatotic liver disease, assessing fibrosis, and stratifying hepatocellular carcinoma risk: a scoping review

Development and validation of a prediction model for psychological distress in patients with differentiated thyroid cancer undergoing ¹³¹I therapy

Ferroptosis in chemotherapy resistance and resensitization in breast cancer: a systematic review of preclinical evidence and translational implications